Form 8-K - Current report:
SEC Accession No. 0001437749-25-012303
Filing Date
2025-04-17
Accepted
2025-04-17 17:24:51
Documents
16
Period of Report
2025-04-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20250417_8k.htm   iXBRL 8-K 29156
2 EXHIBIT 5.1 ex_803193.htm EX-5.1 11037
7 a01.jpg GRAPHIC 4635
  Complete submission text file 0001437749-25-012303.txt   204203

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20250417.xsd EX-101.SCH 4041
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20250417_def.xml EX-101.DEF 13413
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20250417_lab.xml EX-101.LAB 17610
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20250417_pre.xml EX-101.PRE 13390
18 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20250417_8k_htm.xml XML 4739
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 25848525
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)